- Home
- NEWS
2023
-
- patent2023/02/10
-
- Rospatent Grants AskAt a Patent for the AAT-076 Production Process
- AskAt received an Official Decision of Grant dated February 1, 2023 from the Russian Federal Service for Intellectual Property, Patents and Trademarks (Rospatent) for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The notice was issued in connection with Russian Patent Application No. 2021124682 (Filing Date: January 20, 2020).
-
- business2023/01/11
-
- Combined Clinical Trial Application of Cannabinoid CB2 Receptor Agonist AAT-730 for First-In-Human Clinical Trial has been submitted by Oxford Cannabinoid Technologies to UK Regulatory Agencies
- Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO:Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced that a combined clinical trial application for AAT-730 (OCT461201) has been successfully submitted to UK Medicines & Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) on January 4th, 2023.
-
- science2023/01/11
-
- Ikena Oncology presented results of a clinical trial of grapiprant (AAT-007/IK-007) in patients with advanced microsatellite stable colorectal cancer
- Ikena Oncology presented results of a clinical trial of IK-007 in patients with advanced microsatellite stable colorectal cancer at ESMO Immuno-Oncology Annual Congress 2022. For details, please refer an abstract of the presentation at congress homepage.
-
- patent2023/01/06
-
- European Patent Office Grants AskAt EP4 Receptor Antagonist Use Patent for the Treatment of Cartilage Disease
- AskAt received a notice of the decision to grant a European patent pursuant to Article 97(1) EPC from the European Patent Office as of December 8, 2022. This grant of European Patent Application No. 14768803.0 (Filing Date: March 19, 2014), is an EP4 receptor antagonist use patent for the treatment of cartilage disease.
- NEWS
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2013
